Many of the mega M&A deals rarely work out, explains Breakingviews.
Shares of Alere re-open for trading as the company claims Abbott's lawsuit is "entirely without merit." CNBC's Seema Mody reports.
CNBC's David Faber reports the latest on Abbott Laboratories going to court in Delaware to end its proposed acquisition of Alere.
Everyone from government to independent foundations are funding microbiome research. Why bacteria's DNA is garnering so much attention.
Jim Cramer rattles off his take on caller favorite stocks, including this pharma stock that has him reaching for aspirin.
Jim Cramer has seen winners and losers, but this stock takes the cake as the ugliest of the year.
Stocks closed mostly higher on Wednesday following the release of key economic data from the Federal Reserve.
U.S. stock index futures pointed to a flat open, as investors got ready to wade through another influx of earnings reports.
Earnings news could drive stocks Wednesday with several dozen S&P 500 companies reporting and a potential end to the earnings recession in sight.
Stocks closed higher on Tuesday, helped by stronger-than-expected quarterly reports and after mixed inflation data.
Stocks closed lower as investors digested a number of corporate results, key economic data and remarks from a key Fed official.
Corporate earnings, economic reports and Fed speakers could all challenge markets, but so might the election.
Jim Cramer shares the stocks and events on his radar next week.
The “Fast Money” traders and Stephanie Link, TIAA Global Asset Management take their positions on five stocks making news today, including Twilio Inc., Alcoa Inc. and more.
Jim Cramer explains what to watch ahead of the open.
U.S. is the best house to invest in a bad neighbhorhood.
The company said the deal is expected to close in the first quarter of 2017.
Johnson & Johnson will acquire Abbott Laboratories' eye-surgery equipment unit for $4.3 billion in cash. CNBC's Seema Mody reports.
Alere fell 3 percent after it sued Abbott to compel it to get all antitrust approvals required to complete its $5.8 billion merger.
Shares of St. Jude Medical could drop to $55 or lower if the Abbott Laboratories' deal falls apart, Muddy Waters' Carson Block said.